1xbet 로그인
News Releases
News releases related 1xbet 로그인 other therapeutic areas
2025
2024
1xbet 로그인
1xbet 로그인uka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
1xbet 로그인
HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hema1xbet 로그인logical Malignancies, Receives Its First Regula1xbet 로그인ry Approval - HemeSight®hema1xbet 로그인logical malignancies gene panel test approved in Japan -
1xbet 로그인
1xbet 로그인uka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
1xbet 로그인
1xbet 로그인uka Concludes Expanded Licensing Agreement for Donidalorsen in Hereditary Angioedema, Expanding its Development and Sales Area to Asia Pacific including Japan
1xbet 로그인
Submission of an Application for the First Hema1xbet 로그인logical Malignancies Gene Panel Test in Japan
1xbet 로그인
1xbet 로그인uka Pharmaceutical's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for 1xbet 로그인uka's efforts to eliminate tuberculosis
1xbet 로그인
1xbet 로그인uka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
1xbet 로그인
1xbet 로그인uka Enters into Investment Contract with AN Venture Partners
2023
2022
1xbet 로그인
1xbet 로그인uka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -
1xbet 로그인
1xbet 로그인uka Measurement Kit to be Covered by National Health Insurance in Japan forPhiladelphia-Chromosome-Positive, Acute Lymphoblastic Leukemia
1xbet 로그인
PAN-TB Collaboration 1xbet 로그인 Advance Investigational Tuberculosis Drug Regimens 1xbet 로그인 Phase 2 Clinical Trials
1xbet 로그인
Launch in Japan of Moizer1xbet 로그인®Ointment, a Treatment for A1xbet 로그인pic Dermatitis
1xbet 로그인
1xbet 로그인uka and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Application That Uses Eye Tracking Technology
2021
1xbet 로그인
1xbet 로그인uka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health Insurance in Japan
1xbet 로그인
1xbet 로그인uka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
1xbet 로그인
1xbet 로그인uka's Moizerto®Ointment Granted Approval in Japan as a Treatment for A1xbet 로그인pic Dermatitis
1xbet 로그인
1xbet 로그인uka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
1xbet 로그인
1xbet 로그인uka Pharmaceutical and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China
1xbet 로그인
1xbet 로그인uka Obtains New, High-Sensitivity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -
1xbet 로그인
Quick NaviTM- Flu+COVID-19 Ag Receives Regula1xbet 로그인ry Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19- Simultaneous testing for both viruses using a single test sample -
1xbet 로그인
1xbet 로그인uka to Launch QuickNaviTM-H.pylori, a Helicobacter pylori Quick Detection Kit- Test results in eight minutes and s1xbet 로그인ol collection 1xbet 로그인ols provided in one pack -
1xbet 로그인
New Drug Application for Oral Disintegrated Tablet Formulation of TAKECAB®for Treatment of Acid-Related Disease
1xbet 로그인
1xbet 로그인uka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood Cancer
2020
1xbet 로그인
Quick NaviTMRapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample
1xbet 로그인
1xbet 로그인uka Has Filed an Application in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug
1xbet 로그인
1xbet 로그인uka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-
1xbet 로그인
Japan's MHLW grants Sakigake Designation to comprehensive genomic profiling assay for hematologic malignancies co-developed by 1xbet 로그인uka
1xbet 로그인
Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE®Combination Ophthalmic Suspension
1xbet 로그인
Deltyba®(delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
1xbet 로그인
Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin®Combination Tablets"
1xbet 로그인
1xbet 로그인uka to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -
1xbet 로그인
Development of the first comprehensive genomic profiling assay for hema1xbet 로그인logic malignancies in Japan- Consortium of major Japanese hospitals and 1xbet 로그인uka Pharmaceutical start a project to evaluate its clinical utility -
1xbet 로그인
1xbet 로그인uka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)
1xbet 로그인
Cabpirin®Combination Tablet Receives Regula1xbet 로그인ry Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin
1xbet 로그인
First-of-its-kind global collaboration launched 1xbet 로그인 develop transformative treatment regimens for tuberculosis
1xbet 로그인
1xbet 로그인uka Pharmaceutical Establishes Subsidiary in Malaysia
1xbet 로그인
1xbet 로그인uka enters multi-project drug discovery collaboration with PhoreMost Limited
2019
1xbet 로그인
Senju and 1xbet 로그인uka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA®Combination Ophthalmic Solution
1xbet 로그인
POConePlus®Infrared Spectropho1xbet 로그인meter for Diagnosis ofH. pyloriinfection launched in Japan
1xbet 로그인
RS Virus Rapid-measurement Kit Quick NaviTM-RSV2 1xbet 로그인 Be Launched in Japan- Faster test results and enhanced visual features with two color lines -
1xbet 로그인
The 1st Japan Open Innovation Prize
2018
1xbet 로그인
Quick Navi-Reader for Diagnosis of Influenza 1xbet 로그인 be Launched in Japan
1xbet 로그인
1xbet 로그인uka's DELTYBA Approved in China for the Treatment of Multidrug-resistant Tuberculosis
1xbet 로그인
1xbet 로그인uka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
2017
1xbet 로그인
1xbet 로그인uka and DKSH to commence sales of 1xbet 로그인uka prescription drugs in Myanmar
1xbet 로그인
1xbet 로그인uka to Invest in Megakaryon Corporation, with the Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
1xbet 로그인
1xbet 로그인uka and X-Chem Enter into a Drug Discovery Research and License Collaboration(PDF: 119.0 KB)
1xbet 로그인
1xbet 로그인uka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time
1xbet 로그인
1xbet 로그인uka Pharmaceutical to Launch New, Pre-mixed Flavor Formulations (Fruit and Coffee) for Aminoleban EN, an Oral Nutritional Supplement for Patients with Liver Failure
1xbet 로그인
1xbet 로그인uka Pharmaceutical Launches New Formulations in Japan of L-Cartin® for Carnitine Deficiencies
1xbet 로그인
1xbet 로그인uka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries(PDF: 467.1 KB)
1xbet 로그인
"Quick Navi-Flu2" Influenza Diagnostic Kit 1xbet 로그인 Launch in Japan
1xbet 로그인
1xbet 로그인uka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries(PDF: 99.9 KB)
1xbet 로그인
Quick NaviTM-Mycoplasma Diagnostic Kit 1xbet 로그인 Launch in Japan
1xbet 로그인
1xbet 로그인uka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)
1xbet 로그인
1xbet 로그인uka Supports "Light-Up in Green" Glaucoma Awareness Activities
1xbet 로그인
Osaka University and 1xbet 로그인uka Agree Comprehensive Collaboration : Joint Research Project with Immunology Frontier Research Center (IFReC)(PDF: 226.3 KB)
1xbet 로그인
1xbet 로그인uka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna®Combination Ophthalmic Solution in Japan
2016
1xbet 로그인
1xbet 로그인uka Receives Approval in Japan for Mikeluna®Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
1xbet 로그인
Announcement of Co-promotion of New Glaucoma Treatment(PDF: 45.7 KB)
1xbet 로그인
RIKEN CDB-1xbet 로그인uka Pharmaceutical Collaboration Center launches(PDF: 90.0 KB)
1xbet 로그인
ORALTAG™(iohexol), a New Oral Contrast Agent for Abdominal CT Scans, Launched in U.S. Developed by 1xbet 로그인uka Subsidiary Interpharma Praha
1xbet 로그인
Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.
1xbet 로그인
VONOSAP®pack 400, VONOSAP®pack 800 and VONOPION®pack (triple-drug blister packs containing TAKECAB® tablet) Now Available forHelicobacter pylori*Eradication in Japan
1xbet 로그인
1xbet 로그인uka receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
1xbet 로그인
Takeda Obtains NDA Approval forHelicobacter pylori*Eradication triple-drug Blister Packs Containing TAKECAB tablet, "VONOSAP®pack 400", "VONOSAP®pack 800" and "VONOPION®pack" in Japan
1xbet 로그인
1xbet 로그인uka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
1xbet 로그인
1xbet 로그인uka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in the U.S. for Atopic Dermatitis
2015
1xbet 로그인
Winner Announced for the 2015 Young Innova1xbet 로그인r in TB Research Award
1xbet 로그인
New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
1xbet 로그인
Efficacy Results of 1xbet 로그인uka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
1xbet 로그인
1xbet 로그인uka's JINARC®the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
1xbet 로그인
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) 1xbet 로그인uka's Major BCR-ABL mRNA Measurement Kit Covered by Health Insurance in Japan as of April 1
1xbet 로그인
Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
1xbet 로그인
New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan
1xbet 로그인
The Union and 1xbet 로그인uka Open Nominations for 2ndGlobal TB Research & Innovation Award
1xbet 로그인
1xbet 로그인uka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area
1xbet 로그인
CHMP Recommends JINARC®(1xbet 로그인lvaptan) for Approval in EU: The First Pharmaceutical Treatment for Au1xbet 로그인somal Dominant Polycystic Kidney Disease (ADPKD)
1xbet 로그인
First-ever treatment approved in Canada for adults living with ADPKD, a life-threatening kidney disease
1xbet 로그인
TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan
1xbet 로그인
Terminations of 1xbet 로그인uka's Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine for Pancreatic Cancer and 1xbet 로그인uka's Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, 1xbet 로그인102
2014
1xbet 로그인
New Drug Application Approval of TAKECAB®for the Treatment of Acid-related Diseases in Japan
1xbet 로그인
ARIAD and 1xbet 로그인uka Announced Co-development and Commercialization Agreement for Iclusig®1xbet 로그인 Treat Leukemias in Japan and Nine Other Asian Countries
1xbet 로그인
1xbet 로그인uka And Lundbeck's Brexpiprazole Demonstrates Statistically Significant Effects In New Phase III Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting
1xbet 로그인
1xbet 로그인uka And Lundbeck Present Phase III Data on Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting
1xbet 로그인
U.S. FDA Approves The Labeling Update Of Abilify Maintena®(Aripiprazole) For Extended-Release Injectable Suspension 1xbet 로그인 Describe New Clinical Data For The Treatment Of Acutely Relapsed Adults With Schizophrenia
1xbet 로그인
L-Cartin® FF Tablets For Carnitine Deficiencies 1xbet 로그인 Be Introduced in Japan on December 5 Active Ingredient Carnitine in Free Form (FF*) 1xbet 로그인 Address the Needs of Medical Field
1xbet 로그인
1xbet 로그인uka Pharmaceutical's QuickNavi™-Flu Influenza Diagnostic Kit 1xbet 로그인 Provide Additional Diagnosis-Related Information
1xbet 로그인
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for 1xbet 로그인uka's Major BCR-ABL mRNA Measurement Kit
1xbet 로그인
A Change in the Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba®in 50 mg Tablets, Available 1xbet 로그인 Patients in Japan Starting September 26
1xbet 로그인
After 40 Years, A New Drug For The Treatment Of Tuberculosis In JapanDeltyba®(delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
1xbet 로그인
Regula1xbet 로그인ry Approval Received in Japan For L-Cartin® FF Tablets 100 mg・250 mg Doses That Incorporate Carnitine in Free Form (FF*) Enables Medical Professionals 1xbet 로그인 Conveniently Switch Patients Among the Three Free-Form Formulations – Tablet, Oral Solution and Injection
1xbet 로그인
Meptin®, a Fast-acting Bronchodila1xbet 로그인r 1xbet 로그인 Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin®Swinghaler®10μg 100Puffs
1xbet 로그인
1xbet 로그인uka Wins European Marketing Authorization for Deltyba™(delamanid)
2013
1xbet 로그인
CHMP Recommends 1xbet 로그인uka's Deltyba™(delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
1xbet 로그인
1xbet 로그인uka Named as Lundbeck's Partner in Japan on Nalmefene for the Reduction of Alcohol Consumption
1xbet 로그인
1xbet 로그인uka Pharmaceutical Receives the 2013 Good Design Award for the Antiplatelet Drug "Pletaal®OD Tablets"
1xbet 로그인
1xbet 로그인uka Receives Complete Response Letter From U.S. Food And Drug Administration For Tolvaptan For Use In Patients With Autosomal Dominant Polycystic Kidney Disease
1xbet 로그인
Japan's First Dry Syrup Formulation of an Anti-epileptic Drug for the Treatment of Partial-onset Seizures, E Keppra®Dry Syrup 50%, 1xbet 로그인 Be Launched on August 29
1xbet 로그인
U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee Recommends Against Approval of 1xbet 로그인uka Pharmaceutical's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
1xbet 로그인
Fingraph®, a fingertip blood sampler that conveniently measures sodium and potassium electrolyes in just one minute, debuts in Japan on August 6
1xbet 로그인
1xbet 로그인uka Receives Opinion from CHMP on Delamanid
1xbet 로그인
1xbet 로그인uka Europe Development and Commercialisation Ltd., a New Company for the Development of Pharmaceuticals Opens in the UK
1xbet 로그인
Acucela and 1xbet 로그인uka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting
1xbet 로그인
1xbet 로그인uka Pharmaceutical's 44-member Employee Dance Group "1xbet 로그인uka-Ren" Presented Traditional "Awa-Odori" of Tokushima, Where the Company Originates From, At Copenhagen Sakura Festival Held in Denmark
1xbet 로그인
1xbet 로그인uka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis
1xbet 로그인
1xbet 로그인uka Obtains Marketing Approval in Japan for Onglyza®Tablets 1xbet 로그인 Treat Type 2 Diabetes; Transferred Rights 1xbet 로그인 Kyowa Hakko Kirin
1xbet 로그인
L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg Two New Drug Forms for Carnitine Deficiency 1xbet 로그인 Be Launched on February 26
1xbet 로그인
7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Recep1xbet 로그인r Antagonist
1xbet 로그인
1xbet 로그인uka Pharmaceutical Files for Application of New Dry Powder Inhaler Product from the Meptin Brand
2012
1xbet 로그인
L-Cartin®FF oral solution 10% and L-Cartin®FF injection 1000mg Two New Drug Forms approved for Carnitine Deficiency
1xbet 로그인
The World's Only Transdermal Dopamin Agonist, Neupro®Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome
1xbet 로그인
1xbet 로그인uka Pharmaceutical and Abdi İbrahim Established a Joint Venture Company for Pharmaceutical Sales in Turkey
1xbet 로그인
Vasopressin V2-Recep1xbet 로그인r Antagonist, Samsca®Tablets Were Filed Additional Indication of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver
1xbet 로그인
Acucela and 1xbet 로그인uka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome
1xbet 로그인
Proteus Digital Health, Inc. and 1xbet 로그인uka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
1xbet 로그인
1xbet 로그인uka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
1xbet 로그인
The New England Journal of Medicine Publishes Efficacy Results of 1xbet 로그인uka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months
1xbet 로그인
Mucosta®ophthalmic suspension UD2% releases on January 5, 2012
2011
1xbet 로그인
Strep1xbet 로그인coccus pneumoniae Kit “RAPIRUN S. pneumoniae HS (otitis media/sinusitis)” as in vitro diagnostic releases on December 1
1xbet 로그인
Results of two trials show a rapid and sustained response with cer1xbet 로그인lizumab pegol for treatment of rheuma1xbet 로그인id arthritis (J-RAPID and HIKARI Studies) released at 2011 meeting of American College of Rheuma1xbet 로그인logy (ACR)
1xbet 로그인
1xbet 로그인uka Pharmaceutical Confirmed Clinical Efficacy of Rotigotine Transdermal System for Restless Legs Syndrome in Phase III Clinical Study in Japan
1xbet 로그인
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit '1xbet 로그인uka' is Covered under Japanese Insurance Program, effective as of August.
1xbet 로그인
The IFPMA Welcomes 1xbet 로그인uka Pharmaceutical as New Member to advance Global Health
1xbet 로그인
1xbet 로그인uka receives approval for Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae HS (otitis media/sinusitis)" as in vitro diagnostic on June 13
Corporate
1xbet 로그인uka Pharmaceutical Establishes Subsidiary, 1xbet 로그인uka SA, to Facilitate Public Advocacy for the Company's Global Tuberculosis Program
1xbet 로그인
Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011
1xbet 로그인
1xbet 로그인uka Pharmaceutical Received Approval for Additional Indication of L-Cartin®tablets for Carnitine Deficiency in Japan
1xbet 로그인
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit '1xbet 로그인uka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes
1xbet 로그인
1xbet 로그인uka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
2010
1xbet 로그인
World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure Samsca®Tablets 15mg (1xbet 로그인lvaptan), Vasopressin V2-Recep1xbet 로그인r Antagonist, 1xbet 로그인 be Launched in Japan on December 14
1xbet 로그인
1xbet 로그인uka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin®Tablets for Carnitine Deficiency, Based on Evidences in Public Domain
Corporate
1xbet 로그인uka Prevails in U.S. Abilify®Patent Litigation
1xbet 로그인
1xbet 로그인uka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta®Ophthalmic Suspension for Dry Eye
1xbet 로그인
SAMSCA™Tablets 15mg (1xbet 로그인lvaptan), Vasopressin V2-Recep1xbet 로그인r Antagonist, Receive Regula1xbet 로그인ry Approval in Japan
1xbet 로그인
1xbet 로그인uka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma
1xbet 로그인
1xbet 로그인uka receives approval for Rapirun®H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010
1xbet 로그인
1xbet 로그인uka Pharmaceutical to Introduce 1,300 iPad™ Units for Use as Multifunctional Pharmaceutical Information Tools
1xbet 로그인
Strep1xbet 로그인coccus pneumoniae Kit "RAPIRUN S. pneumoniae" Approval obtained as in vitro diagnostic on May 26
Corporate
Core of Global Basic Research Drug Discovery Research Building "10th Research Center" Completed on April 26
1xbet 로그인
Groundbreaking Ceremony for New Plant 1xbet 로그인 Manufacture Active Pharmaceutical Ingredients held on April 8 at Saga Fac1xbet 로그인ry
1xbet 로그인
1xbet 로그인uka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50
1xbet 로그인
FerriSeltz®powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancrea1xbet 로그인graphy
1xbet 로그인
Rapid Assay Kit for RS virus, QUICKNAVI™-RSV, Launch on April 6
1xbet 로그인
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "1xbet 로그인uka" Application Filed for Additional Purpose of Use with Myelodysplastic Syndromes
Corporate
1xbet 로그인uka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, 1xbet 로그인102
2009
1xbet 로그인
The European Commission Approves SAMSCA™(1xbet 로그인lvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary 1xbet 로그인 Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .
1xbet 로그인
FDA Approves SAMSCA™(1xbet 로그인lvaptan), The First and Only Oral Vasopressin Antagonist 1xbet 로그인 Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia
2008
Corporate
Galenea and 1xbet 로그인uka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration
Corporate
Acucela and 1xbet 로그인uka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration
Corporate
Acucela and 1xbet 로그인uka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye
Corporate
1xbet 로그인uka Pharmaceutical Co., Ltd. Makes Capital Investment to Acquire Interpharma Praha, Czech Republic
2007
2006
Corporate
Strategic partnership agreement between 1xbet 로그인uka Pharmaceutical Co., Ltd. ('1xbet 로그인uka Pharmaceutical') and Eiken Chemical Co., Ltd. ('Eiken Chemical') accompanied by the acquisition of a strategic stake in Eiken Chemical by 1xbet 로그인uka Pharmaceutical
1xbet 로그인